Glenmark Says Gujarat Plant Cleared By U.S. Drug Regulator

Glenmark Says Gujarat Plant Cleared By U.S. Drug Regulator
Tablets sit on a conveyor belt at a pharmaceutical manufacturing facility (Photographer: Dhiraj Singh/Bloomberg)

Glenmark Pharmaceuticals Ltd. said its Ankleshwar plant in Gujarat has been cleared by the U.S. drug regulator after an inspection.

The plant received an establishment inspection report (EIR) from the U.S. Food and Drug Administration FDA) on Tuesday, the company said in a filing to the Bombay Stock Exchange Ltd. (BSE).

The EIR is issued by the U.S. FDA only if it finds the facility to be deemed acceptable, the filing said.

The stock gained as much as 4.5 percent to touch Rs 929, from Tuesday's closing.

Glenmark clarified to the stock exchange over a news report which claimed that its Ankleshwar plant received observations from the U.S. FDA during its inspection in December 2016.

Unlock this article for free
Sign up to access exclusive stories, fewer ads, and a personalised experience.
Set as Trusted Source
on Google Search